Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 16:14:1027-1040.
doi: 10.2147/PGPM.S316711. eCollection 2021.

Population Genetic Difference of Pharmacogenomic VIP Variants in the Tibetan Population

Chunjuan He  1 , Linna Peng  1 , Shishi Xing  1 , Dandan Li  1 , Li Wang  1 , Tianbo Jin  1   2
Affiliations

Population Genetic Difference of Pharmacogenomic VIP Variants in the Tibetan Population

Chunjuan He et al. Pharmgenomics Pers Med. .

Abstract

Background: Genetic variation influences drug reaction or adverse prognosis. The purpose of this research was to genotype very important pharmacogenetic (VIP) variants in the Tibetan population.

Methods and materials: Blood samples from 200 Tibetans were randomly collected and 59 VIP variants were genotyped, and then compared our data to 26 other populations in the 1000 project to further analyze and identify significant difference.

Results: The results showed that on comparing with most of the 26 populations from the 1000 project, rs4291 (ACE), rs1051296 (SLC19A1) and rs1065852 (CYP2D6) significantly differed in the Tibetan population. Furthermore, three significant loci were related to drug response. In addition, the allele frequency of Tibetans least differed from that of East Asian populations, and most differed from that of Americans.

Conclusion: Three significant loci of variation ACE rs4291, SLC19A1 rs1051296 and CYP2D6 rs1065852 were associated with drug response. This result will contribute to improving the information of the Tibetan in the pharmacogenomics database, and providing a theoretical basis for clinical individualised drug use in Tibetans.

Keywords: VIP variants; pharmacogenomics; the Tibetan population.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

References

    1. Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev. 2011;63(2):437–459. doi:10.1124/pr.110.003533 - DOI - PubMed
    1. Wang L, Aikemu A, Yibulayin A, et al. Genetic polymorphisms of pharmacogenomic VIP variants in the Uygur population from northwestern China. BMC Genet. 2015;16(1):66. doi:10.1186/s12863-015-0232-x - DOI - PMC - PubMed
    1. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343–350. doi:10.1038/nature15817 - DOI - PMC - PubMed
    1. Jin T, Zhao R, Shi X, et al. Genetic polymorphisms study of pharmacogenomic VIP variants in Han ethnic of China’s Shaanxi province. Environ Toxicol Pharmacol. 2016;46:27–35. doi:10.1016/j.etap.2016.06.026 - DOI - PubMed
    1. Evans WE, McLeod HL. Pharmacogenomics–drug disposition, drug targets, and side effects. N Engl J Med. 2003;348(6):538–549. doi:10.1056/NEJMra020526 - DOI - PubMed